Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseobservationalRules rewrite

Not a traditional drug phase: Questionnaire for Neuroendocrine Cervical Cancer

To learn about the effects of a participant support community on illness perception, emotional well-being, and feelings of isolation among participants with NECC.

Official registry: https://clinicaltrials.gov/study/NCT07532954 · M.D. Anderson Cancer Center · enrollment listed as 40

What this phase means

This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.

They plan to enroll about 40 people at Houston. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support

Interventions: Questionnaire

Primary outcome (registry wording): Demographic questionnaire

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Eligibility Criteria
  • Histologically confirmed NECC
  • Aged 18 years or older
  • English proficient
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Access to necessary resources for participating in a technology-based intervention (i.e., computer, smartphone, internet access)

Public study contact (from the registry)

Larissa Meyer, MD

Meyer

lmeyer@mdanderson.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseScottsdale, Arizona
Not a traditional drug phase: Quality-of-Life Assessment for Cervical Carcinoma

This early phase I trial compares the side effects between patients treated with proton radiation therapy versus intensity modulated radiation therapy after surgery for the treatment of endometrial or cervical cancer. Radiation therapy uses high energy protons or x-rays to kill tumor cells and shrink tumors.

NCT04567771 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: Vaginal Fluid Collection for Endometrial Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid.

NCT05051722 · Official ClinicalTrials.gov record · Mayo Clinic

RecruitingNot a traditional drug phaseDuarte, California
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

This is an watch-and-measure (no experimental treatment required) case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gastric, head and neck, hepatobiliary, leukemia, lung, lymphoma, multiple myeloma, ovarian, pancreatic, prostate, renal, sarcoma, and thyroid.

NCT05366881 · Official ClinicalTrials.gov record · Adela, Inc

FAQ about this NCT record

Is NCT07532954 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07532954?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07532954?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary